Buchumschlag

Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Jincheng Yang, Damilola Olabode, Aarti Sawant‐Basak, Richard Baldry, Karthick Vishwanathan, Srinivas Bachina, Alexandar Todd, Dana Ghiorghiu, Yuri Rukazenkov, Diansong Zhou, Azar Shahraz
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Clinical Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Reply to “High Pharmacokinetic Variability and Unrecognized Limitations in First‐Line Osimertinib Plus Chemotherapy for EGFR ‐Mutated NSCLC ”
von: Azar Shahraz, et al.
Veröffentlicht: (2025)

A quantitative model‐based approach for adavosertib dose selection in patients with uterine serous carcinoma
von: Shankar Lanke, et al.
Veröffentlicht: (2025)

Learnings from Approved Antibody‐Drug Conjugates: Clinical Pharmacology Perspectives
von: Bhargavi Thalluri, et al.
Veröffentlicht: (2026)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
von: Xin Liao, et al.
Veröffentlicht: (2024)

GCMS and LCMS data of exometabolome of parental and Osimertinib-resistant EGFR-mutant NSCLC
von: Bramanti, Emilia
Veröffentlicht: (2025)

Possible new mechanisms of primary drug resistance in NSCLC with EGFR mutation treated with Osimertinib
von: Lujing Shao, et al.
Veröffentlicht: (2025)

Stochastic Gates for Covariate Selection in Population Pharmacokinetics Modeling
von: Marija Kekic, et al.
Veröffentlicht: (2026)

First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
von: Yugo Matsumura, et al.
Veröffentlicht: (2025)

A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection
von: Azar Shahraz, et al.
Veröffentlicht: (2024)

Osimertinib Cost Minimization in Non‐Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat
von: Niels Westra, et al.
Veröffentlicht: (2025)

Clinical Outcomes of Later‐Generation EGFR ‐ TKIs for Uncommon EGFR Mutations in NSCLC : A Multicenter Real‐World Study
von: Lisa Shigematsu, et al.
Veröffentlicht: (2025)

Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes
von: Yutaro Nagano, et al.
Veröffentlicht: (2026)

Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations
von: Yuko Iida, et al.
Veröffentlicht: (2026)

Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors
von: Martin Johnson, et al.
Veröffentlicht: (2024)

Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial
von: Huiyang Shi, et al.
Veröffentlicht: (2025)

Orthoallosteric EGFR‐TKIs: A New Paradigm in NSCLC Treatment Strategy Targeting the C797S Mutation
von: Iqrar Ahmad, et al.
Veröffentlicht: (2024)

Magnoliae flos Overcomes EGFR ‐ TKI Resistance in NSCLC by Enhancing EGFR Ubiquitination
von: Qing Wu, et al.
Veröffentlicht: (2026)

Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study
von: Yu Hua, et al.
Veröffentlicht: (2025)

Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation
von: Xiaohui Du, et al.
Veröffentlicht: (2025)

Multieffect Specific Nanovesicles for Homing Resistant Tumors and Overcoming Osimertinib‐Acquired Resistance in NSCLC
von: Yuanyao Dou, et al.
Veröffentlicht: (2025)

More treatment options emerge for EGFR ‐mutant NSCLC
von: Leah Lawrence
Veröffentlicht: (2026)

Highly Specific Cytokine Receptor‐Targeting Chimeras for Targeted Membrane Protein Degradation and Sensitization of Osimertinib in EGFR‐Mutated Non‐Small‐Cell Lung Cancer
von: Jiawei Wu, et al.
Veröffentlicht: (2025)

Successful Treatment of Osimertinib Resistance in an EGFR‐Mutant Lung Cancer Patient With a Rare STRN3‐ALK Fusion Using Brigatinib and Osimertinib
von: Chia‐Yu Kuo, et al.
Veröffentlicht: (2025)

Sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR‐mutant advanced NSCLC
von: Leah Lawrence
Veröffentlicht: (2026)

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
von: Kei Sonehara, et al.
Veröffentlicht: (2024)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
von: Jin Tian, et al.
Veröffentlicht: (2024)

Persist or resist: Immune checkpoint inhibitors in EGFR‐mutated NSCLC
von: Pengcheng Zhu, et al.
Veröffentlicht: (2024)

Integrin αV Inhibition by GMI, a Ganoderma Microsporum Immunomodulatory Protein, Abolish Stemness and Migration in EGFR‐Mutated Lung Cancer Cells Resistant to Osimertinib
von: Yu‐Ting Kang, et al.
Veröffentlicht: (2024)

USP28 Promotes Osimertinib Resistance in H1975 NSCLC Cells by Deubiquitinating and Stabilizing SIRT1
von: Hu‐Sen Fan, et al.
Veröffentlicht: (2025)

Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR‐TKI Treatment: A Retrospective Cohort Study
von: Yi‐Tse Su, et al.
Veröffentlicht: (2025)

The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis
von: Liuxian Guo, et al.
Veröffentlicht: (2024)

L858R / L718Q and L858R / L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds
von: Ibrahim A. Imam, et al.
Veröffentlicht: (2024)

Nomogram for Predicting Efficacy and Prognosis After Chemotherapy for Advanced NSCLC
von: Jiaying Gao, et al.
Veröffentlicht: (2024)

Wende und Übergang
von: Alexandrov, Alexandar
Veröffentlicht: (2017)

Higher-dimensional Holographic Superconductors in Born-Infeld Electrodynamics and f(R) Gravity
von: Roussev, Alexandar
Veröffentlicht: (2023)

Customer Behaviour Analysis Through Clustering and Classification for Segmentation and Forecasting in Marketing Campaigns - Figure 1
von: Alexandar Danailov
Veröffentlicht: (2025)

Revolution and Transition
von: Alexandrov, Alexandar
Veröffentlicht: (2017)

Mikhail Bakhtin and the Eucharist “Religio Laici: Mikhail Bakhtin’s Orthodoxies”
von: Alexandar Mihailovic
Veröffentlicht: (2015)

Itraconazole Reversing Acquired Resistance to Osimertinib in NSCLC by Inhibiting the SHH/DUSP13B/p‐STAT3 Axis
von: Hongmei Zheng, et al.
Veröffentlicht: (2024)

Environmental impact assessment of settlement and development in the upper Léraba basin : Burkina Faso, Côte d'Ivoire, and Mali / David Baldry, Davide Calamari, Laurent Yaméogo
von: Baldry, David
Veröffentlicht: (1995)